Novartis
Viewpoint: Spinal muscular atrophy treatment Zolgensma a gene therapy trailblazer, despite controversy
In August, the US Food and Drug Administration (FDA) gave drug manufacturer AveXis, Inc, a subsidiary of Novartis AG, a ...
Animal safety concerns prompt FDA to halt study testing Zolgensma gene therapy for spinal muscular atrophy
The Food and Drug Administration has halted a clinical trial of Novartis’ Zolgensma gene therapy due to a safety concern ...
Application for pricey gene therapy Zolgensma contained manipulated data, but drug will remain on market, FDA says
The Food and Drug Administration said Tuesday [August 7] that Novartis submitted manipulated data as part of its application for ...
Growing criticism over stratospheric cost of spinal muscular atrophy-fighting drug Zolgensma ignores trade-off value
Novartis recently won FDA approval for Zolgensma, a new medicine that can potentially cure infants suffering from the otherwise fatal ...
